News | PET-CT | June 07, 2016

Sodium Fluoride PET-CT Predicts Advanced Prostate Cancer Outcomes

Study finds NAF-PET/CT more accurately detects bone metastases while improving long-term clinical outcomes and survival

NaF-PET/CT, sodium fluoride, advanced prostate cancer, metastases, pilot study

June 7, 2016 — A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients with advanced prostate cancer. The study also found follow-up scans over time correlate clearly with clinical outcomes and patient survival. 

According to the Centers for Disease Control and Prevention, in 2012 (the most recent year for which numbers are available) 177,489 men in the United States were diagnosed with prostate cancer, and 27,244 men in the U.S. died from the disease.

Andrea B. Apolo, M.D., chief of the Bladder Cancer Section, Center for Cancer Research, at the National Cancer Institute in Bethesda, Md., said, “To our knowledge, this is the first report of follow-up NaF scans of prostate cancer patients over a one-year period correlated with survival. The findings in this study provide support for the use of NaF-PET/CT in clinical practice in patients with advanced prostate cancer.”

Sixty prostate cancer patients, including 30 with and 30 without known bone metastases by conventional imaging, underwent NaF-PET/CT at baseline, six and 12 months. Positive lesions were verified on follow-up scans. Changes in standardized uptake values (SUV) and lesion number were correlated with prostate-specific antigen (PSA) change, clinical impression and overall survival. Also, greater change in SUV at six and 12 months correlated with greater change in PSA.

In an exploratory analysis, paired Tc-99m-MDP bone scans (TcBS) were available in 35 patients at baseline, 19 at six months and 14 at 12 months. Malignant lesions on NaF-PET/CT were classified on TcBS as malignant only 65 percent of the time; 25 percent were indeterminate; and 10 percent were negative. In addition, 65 percent of paired scans showed more lesions on NaF-PET/CT than on TcBS. 

The study shows that NaF-PET/CT detects more bone metastases earlier than TcBS and enhances detection of new bone disease in high-risk patients.

Apolo stated, “Our study suggests that NaF-PET/CT may be a useful imaging modality in the diagnosis, prognosis and follow-up of prostate cancer patients at high risk for bone metastasis. It provides a strong rationale to further the clinical development of NaF-PET/CT as a bone imaging tool in prostate cancer and other malignancies.”

For more information: www.jnm.snmjournals.org

Related Content

Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...